Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II pilot safety and tolerability study of ILB in patients with Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Phase II pilot safety and tolerability study of ILB in patients with Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dextran sulfate (Primary)
  • Indications Amyotrophic lateral sclerosis; Motor neuron disease
  • Focus Adverse reactions
  • Most Recent Events

    • 16 May 2019 Status changed from planning to recruiting.
    • 06 Sep 2018 New trial record
    • 20 Aug 2018 According to TikoMed media release, Dr. Venkataramanan Srinivasan is principal investigator. The clinical trial will be conducted at and in collaboration with Birmingham University Hospital, Birmingham, United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top